1219707-39-7CN1CCN(c2ccc(N3C[C@H](CO)OC3=O)cc2F)C=N1QLUWQAFDTNAYPN-LLVKDONJSA-NDelpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study).
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins.
Substances that inhibit the growth or reproduction of BACTERIA.
説明Delpazolid is an oxazolidinone antibiotic. It is active against a wide range of Gram-positive bacterial clinical isolates, including resistant strains of several species, such as methicillin-resistant S. aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), and penicillin-resistant S. pneumoniae (MICs = 0.125-4 μg/ml). Delpazolid increases survival in mouse models of systemic MRSA, E. faecalis, S. pneumoniae, and H. influenzae infection (ED50s = 2.96, 4.53, 2.28, and 9.96 mg/kg, respectively).
現在のフィルター条件では反応記録がありません。
読み込み中…
1219707-39-7CHEMBL1673408